BMC Gastroenterology volume  22, Article number: 401 (2022 ) Cite this article

The present study investigates if common missense functional variants p.I148M and p.E167K in PNPLA3 and TM6SF2 genes, respectively, associate with development of hepatic fibrosis and cirrhosis in a geographically novel cohort of Pakistani chronic hepatitis C (CHC) patients.

In total, 502 Pakistani CHC patients [242 males, median age 40 years, 220 with significant hepatic fibrosis, including 114 with cirrhosis] were genotyped for PNPLA3 and TM6SF2 variants using TaqMan genotyping assays. Associations between genotypes, biochemical and clinical parameters were evaluated.

Genotypic distributions for PNPLA3 and TM6SF2 polymorphisms conformed to Hardy–Weinberg equilibrium and did not associate with fibrosis grades ≥ F2 or cirrhosis in any of the genetic models tested (all p =  > 0.05). PNPLA3 and TM6SF2 variants did not modulate baseline characteristics and serum markers of liver injury in CHC patients. Similarly, increasing number of risk alleles of PNPLA3 and TM6SF2 polymorphisms had no trend effect on serum liver enzyme activities or proportion of CHC patients with significant or advanced fibrosis or cirrhosis (p =  > 0.05). The same trend of no association with hepatic fibrosis or cirrhosis persisted in the multivariate logistic regression models adjusting for age, gender, body mass index and HCV viral load (p =  > 0.05).

PNPLA3 and TM6SF2 variants do not appear to modulate development of hepatic fibrosis or cirrhosis in present CHC patients of Pakistani origin, and may be of more relevance in liver pathology involving abnormalities in hepatic fat accumulation. These results also reflect the divergent associations observed for different genetic modifiers of hepatic fibrosis and cirrhosis in distinct ethnicities.

Hepatitis C virus (HCV) infection is a major healthcare problem that has chronically infected 58 million people globally. According to WHO estimates, HCV related death toll in 2019 was around 0.29 million, mostly due to hepatic fibrosis and cirrhosis and hepatocellular carcinoma (HCC) [1]. Pakistan has the second largest burden of HCV around the world, with a nationwide prevalence of about 4.8%. Despite the availability of direct-acting antivirals (DAAs) in Pakistan and an associated reduced cost of treatment, the prevalence of HCV still remains persistent, with no indication of decline [2].

Following chronic Hepatitis C (CHC), the natural history of development and progression of chronic liver pathology (CLP) is highly variable and ranges from marginal histological injury to development of liver scarring and eventually HCC. Various factors of viral [e.g. HCV genotype and co-infection with Human Immunodeficiency Virus (HIV)/Hepatitis B Virus (HBV)], metabolic (e.g. metabolic syndrome) and host genetic factors may contribute towards this variability [3]. Indeed, presence of hepatic steatosis and features of metabolic syndrome (including obesity and diabetes mellitus) have been shown to exacerbate progression of hepatic fibrosis and cirrhosis in CHC settings [4].

The dawn of genome-wide association study (GWAS) approach highlighted the potential role of host genetic factors related to hepatic fat metabolism [including PNPLA3 (adiponutrin or patatin-like phospholipase domain-containing protein 3) and TM6SF2 (transmembrane 6 superfamily member 2) in CLP, mainly in non-alcoholic fatty liver disease (NAFLD) settings [5, 6]. In this context, PNPLA3 rs738409 polymorphism has been found associated with liver fat content [7], as well as with clinical phenotypes of steatosis, steatohepatitis and liver fibrosis/cirrhosis in various hepatic etiologies of non-viral [mainly NAFLD and alcoholic liver disease (ALD)] [8, 9] and viral (mainly CHC) [10, 11] origins. Functionally, carriers of the G allele at the above-mentioned locus have a reduced enzymatic activity of adiponutrin, resulting in high levels of intracellular triglyceride [12], that may subsequently result in the higher predisposition to hepatic scarring and HCC [13].

Similarly, TM6SF2 rs58542926 variant has been reported to associate with increased risk of NAFLD [14], where the minor (T) allele of this missense variant reportedly conferred TM6SF2 functional loss, translating to enhanced aggregation of intrahepatic lipids due to diminished very low density lipoprotein (VLDL) secretion [15]. TM6SF2 also facilitates the lipidation and secretion of newly formed lipoviro-particles (LVPs) [16]. For that reason, TM6SF2 rs58542926 variant has been suggested as a potential risk factor for development of liver fibrosis and cirrhosis and linked to lipid abnormalities in chronic HCV patients [16, 17].

To this point, despite the fact that PNPLA3 and TM6SF2 polymorphisms represent most commonly investigated lipid metabolism based host genetic variants in NAFLD, their potential influence in CHC mediated CLP is less defined. Additionally, PNPLA3 and TM6SF2 variants based genetic predisposition to liver scarring data in CHC patients is mainly available for different Caucasian ethnic groups with scarce representation of other populations, together with Indo-Pak region and mixed populations [18].

In view of the above, the present study explores the association of PNPLA3 p.I148M (rs738409) and TM6SF2 p.E167K (rs58542926) single nucleotide polymorphisms (SNPs) with predisposition to liver scarring in a geographically novel cohort (Pakistani CHC patients) employing independent and adjusted analyses for common confounders of demographic, viral, laboratory and clinical nature that may influence this association.

The details of ethical approvals and consent, patients and samples and their clinical and laboratory evaluations pertaining to this study have been described previously [19]. Briefly, in this cross-sectional comparative study, 502 Pakistani patients with CHC (treatment naive) presenting at a tertiary care hospital in Lahore, Pakistan, were recruited. All patients provided written informed consent for study participation. Ethical guidelines specified in the latest version of Declaration of Helsinki were followed with a priori approval of all study protocols by the Ethical Review Committee for Medical and Biomedical Research, University of Health Sciences, Lahore, Pakistan. CHC was diagnosed considering clinical signs of chronic hepatic ailment along with molecular testing for HCV-RNA. The presence of acute and chronic liver pathologies of non-CHC origin were excluded in all patients. All patients provided venous blood samples for biochemical and genetic analyses and standard demographic, clinical and laboratory evaluation data including liver function tests were recorded for each patient. CHC patients were evaluated for hepatic fibrosis and cirrhosis based on imaging analysis i.e. transient elastography by Fibroscan® (Echosens, Waltham, North America) with probes SN77561 and SN94171, where Ziol transient elastography cut-offs [20] were used to define Metavir fibrosis stages (F0–F3) and cirrhosis (F4) with maximal sensitivity and specificity as used previously [19, 21]. Based on the Metavir fibrosis stages, the significant hepatic fibrosis was defined as ≥ F2, advanced hepatic fibrosis as ≥ F3 and hepatic cirrhosis as F4.

After isolation of genomic DNA from EDTA anti-coagulated blood samples by means of commercially available DNeasy blood kit (Qiagen, Germany), genotyping of above specified target variants in PNPLA3 and TM6SF2 genes was performed using TaqMan genotyping assays (Applied Biosystems, USA) and genotypes were scored using allelic discrimination 7500 Software. All PNPLA3 and TM6SF2 molecular analysis was blinded to any phenotypic and clinical information.

All statistical analyses were undertaken using GraphPad Prism 8.0 and SPSS version 20 for windows unless specified otherwise. Qualitative variables were expressed as frequencies. Whereas, quantitative variables were given as medians with ranges and analyzed using non-parametric Mann–Whitney U or Kruskal–Wallis tests as suitable. Conformance of PNPLA3 and TM6SF2 genotypes with Hardy–Weinberg equilibrium (HWE) was analyzed using Chi-square (χ2) test. Association of PNPLA3 and TM6SF2 allelic and genotypic data with phenotypic variables was tested using contingency tables and trend tests. The effects of PNPLA3 and TM6SF2 genetic variants as well as any additional risk variables [(including age, sex, body mass index (BMI) and log-transformed HCV-RNA] on liver fibrosis and cirrhosis were determined using univariate and multivariate logistic regression models where the later included any additional risk variables with a p-value < 0.20 in univariate analysis, in addition to PNPLA3 and TM6SF2 genotypes. Power calculations were performed using the Genetic Association Study (GAS) power calculator available from http://csg.sph.umich.edu/abecasis/gas_power_calculator/index.html. All tests were two-tailed, and p-values < 0.05 were considered significant.

GTEx (Genotype-Tissue Expression) dataset version 8 harbors expression quantitative trait loci (eQTL) data for different healthy tissue types (including liver and adipose tissue) and is publicly available at https://www.gtexportal.org/. GTEx was queried with PNPLA3 p.I148M and TM6SF2 p.E167K SNP identifiers to determine any genotype specific effect of these variants on tissue specific gene expression patterns and hence establish whether these represent loss of function or eQTL variants with respect to their functional significance.

The baseline data of the present sample set has been described elsewhere [19] and is summarized below. Briefly, among a total of 502 CHC patients, median age was 40 years and there were less men (47.9%) included in the sample set than women. Metavir hepatic fibrosis stage of ≥ F2 was seen in 43.8% CHC patients (including 22.7% cirrhotic cases) (Table 1) and these patients were characterized by significantly higher age, median BMI, HCV-RNA (log10), liver enzymes and total bilirubin (all p =  < 0.05), but not with respect to gender distribution (p =  > 0.05), in comparison with CHC patients presenting with lower grades of hepatic fibrosis (Additional file 1: Supplementary Table 1). Moreover, genotyping efficiency for each of the PNPLA3 p.I148M and TM6SF2 p.E167K SNPs was 99.6% (successfully genotyped in 500 individuals) and their genotypic distributions were similar to those reported for Pakistani population from the 1000 genome project (available at http://browser.1000genomes.org) and also did not deviate from Hardy–Weinberg equilibrium (p =  > 0.05, χ2 tests).

When analyzing association of PNPLA3 rs738409 and TM6SF2 rs58542926 polymorphisms with baseline clinical and laboratory characteristics, PNPLA3 was found to be significantly associated with age (p = 0.008). However, no other associations with baseline characteristics, including liver function tests, were apparent for PNPLA3 and TM6SF2 SNPs (all p =  > 0.05) as presented in Table 2. Also, Fig. 1 demonstrates that no significant increase in serum markers of hepatic injury was evident with an increase in the number of risk alleles of either genetic variant (p =  > 0.05).

Pooled analysis of the PNPLA3 rs738409 and TM6SF2 rs58542926 polymorphisms variant alleles on hepatic enzymes including a ALT and b AST. The frequencies of the respective risk alleles were as follows; 0 risk alleles = 246, 1 risk allele = 127, 2 risk alleles = 39, and 3 risk alleles = 07

Subsequently, we examined any potential role of PNPLA3 rs738409 and TM6SF2 rs58542926 variants in moderating predisposition to significant and advanced hepatic fibrosis, and liver cirrhosis in separate analyses. We detected no significant association of PNPLA3 with liver fibrosis stages F2-F3 and cirrhosis F4 in any of the genetic models tested (p =  > 0.05). Likewise, allele and genotype distributions for TM6SF2 p.E167K missense variant did not differ significantly in CHC patients with or without hepatic fibrosis or cirrhosis even after stratifying the data according to different genetic models (p =  > 0.05). These findings are presented in Tables 3 and 4 and Additional file 2: Supplementary Table 2. Considering the risk allele frequency of PNPLA3 p.I148M variant in the present sample set, these analyses had sufficient power (> 95%) to detect genetic influences on hepatic fibrosis but not on liver cirrhosis (power of study < 50%). The analyses to detect TM6SF2 genetic association with advanced hepatic fibrosis were powered at > 88%, however, the same for determining predisposition to hepatic cirrhosis were underpowered (< 42%). In addition, no statistically significant increasing trend of hepatic fibrosis or cirrhosis was observable with increase in number of PNPLA3 and TM6SF2 risk alleles (Fig. 2).

Proportion of a significant hepatic fibrosis (≥ F2), b advanced hepatic fibrosis (≥ F3), and c hepatic cirrhosis (F4) in all CHC patients with 0, 1, 2 and 3 risk alleles of PNPLA3 and TM6SF2 variants

Next, potential risk factors that may be associated with liver fibrosis and cirrhosis were analyzed using logistic regression models, as summarized in Table 5 and Additional file 3: Supplementary Table 3, the results of which suggest no significant associations of PNPLA3 p.I148M and TM6SF2 p.E167K genotypes with liver fibrosis stages or cirrhosis in univariate and multivariate regression models (all p =  > 0.05). Since BMI was independently associated with hepatic fibrosis and cirrhosis in these analyses, we therefore also stratified CHC patients according to BMI status into obese (BMI ≥ 25) and non-obese (BMI < 25) sub-groups and analyzed for any potential genetic associations of PNPLA3 and TM6SF2 variants. However, no significant genetic associations were observed for hepatic fibrosis and cirrhosis after stratification according to BMI status (all p =  > 0.05), as presented in Additional files 4: Supplementary Fig. 1 and 5: Supplementary Fig. 2.

We further explored genotype-gene expression based functional significance of analyzed genetic variants using GTEx database (Additional files 6: Supplementary Table 4 and 7: Supplementary Table 5) and found that PNPLA3*rs738409 and TM6SF2*rs58542926 do not represent significant eQTLs/sQTLs of PNPLA3 and TM6SF2 gene expression in liver and visceral adipose tissues, but may modulate genotype specific target gene expression in other human peripheral tissues (of note in subcutaneous adipose tissue for TM6SF2*rs58542926 eQTL pair) as presented in Additional files 8: Supplementary Fig. 3 and 9: Supplementary Fig. 4.

PNPLA3 rs738409 and TM6SF2 rs58542926 SNPs, that initially came into highlight from GWAS [5] and EWAS [6] analyses in patients with NAFLD, are important modulators of hepatic fat metabolism and are regarded as significant genetic influencers of liver injury of various etiologies especially steatosis and NAFLD. The current study, which examined these variants in the setting of Pakistani CHC patients, suggests that PNPLA3 and TM6SF2 polymorphisms seem to have no effect on serum markers of hepatic injury nor they associate with development of hepatic scarring following CHC infection.

From a mechanistic perspective, wild-type PNPLA3 has a marked hepatic expression where it exhibits triglyceride lipolytic activity in hepatocytes as well as retinyle-palmitate lipase activity in stellate cells of liver [22]. PNPLA3 p.I148M represents a loss of function variant resulting in reduced lipase activity and gain of hepatic lipogenic activity manifesting as hepatic fat accumulation [23]. It may further promote liver injury by influencing retinol remodeling [24] and promoting production of pro-fibrotic proteins in stellate cells of liver [25]. In a similar way, wild-type TM6SF2 activity mediates Apolipoprotein B (APOB) lipidation and hepatic efflux of triglycerides to circulation through VLDLs [26]. TM6SF2 p.E167K variant affects modulation of triglyceride-rich lipoproteins and APOB thereby increasing hepatic fat content [6, 27]. Altogether, PNPLA3 p.I148M and TM6SF2 p.E167K variants may promote steatosis and steatohepatitis which may indirectly predispose to progression of liver scarring (fibrosis and cirrhosis).

Indeed, the association of PNPLA3 rs738409 and TM6SF2 rs58542926 SNPs with hepatic injury resulting from dysregulation of hepatic lipid metabolism (steatohepatitis and NAFLD) is well established [5, 6, 8, 17, 28], however, extension of their implication in NAFLD-associated hepatic fibrosis is not definite [28] and is certainly debatable in the context of hepatic fibrosis and cirrhosis of viral (especially CHC) etiology [10, 17, 29, 30].

Previously, several studies based on primarily Caucasian and some Asian datasets have suggested association of PNPLA3 risk variant with increased severity of hepatic fibrosis and cirrhosis [30, 31] and enhanced progression of liver fibrosis or cirrhosis [29] or independent steatosis [10, 32] in CHC settings. However, such evidence is relatively limited for TM6SF2 where only a couple of studies reported overrepresentation of TM6SF2 rs58542926 risk allele in CHC patients displaying hepatic scarring (fibrosis and cirrhosis) [30, 33]. Extension of PNPLA3 and TM6SF2 association has also been observed to hepatocellular carcinoma (HCC) [34] attributable to both viral [13] and non-viral [35, 36] origin, and less commonly to alcoholic liver disease [9]. In addition, PNPLA3 and TM6SF2 variants have been regarded as variants of interest for risk of liver steatosis even in transplant settings [37, 38]. However, potential association of PNPLA3 and TM6SF2 genetic polymorphisms with HCC is not without several contradictions [9, 39,40,41].

Nevertheless, in the present CHC patients of Pakistani origin we did not detect any significant effect of PNPLA3 and TM6SF2 variants in modulating serum markers of hepatic injury nor hepatic fibrosis and cirrhosis. The outcomes of our study are in line with two major such studies from Caucasian and Asian populations. Eslam et al. suggested only a marginal association if any (that was not persistent after adjustment for confounders) of TM6SF2 with fibrosis severity and none for fibrosis progression in a large sample set of CHC patients (n = 2023) from the International Liver Disease Genetics Consortium [17]. Likewise, Huang and colleagues demonstrated a role of PNPLA3 variant in HCV induced steatosis but no independent association with liver fibrosis and cirrhosis based on 1080 CHC patients of Chinese ancestry [11]. The same pattern (association of PNPLA3 with steatosis and steatohepatitis but not with hepatic scarring in CHC patients) was also evident from another Caucasian study [10]. Also, no significant impact of PNPLA3 and TM6SF2 variants on hepatic fibrosis and cirrhosis of CHC background was highlighted in some of such studies from other populations [14, 42, 43]. It is noteworthy here that all these studies had biopsy proven staging and diagnoses of hepatic fibrosis and cirrhosis. Interestingly, a couple of studies reported reduced HCV viral load associated with PNPLA3 [29] and TM6SF2 [17] risk alleles, translating to reduced HCV lipidation and infectivity [16], however, no such associations were observed in our study.

Only a single study on the present subject is available from Pakistan that reported a significant prevalence of PNPLA3 risk variant, but not TM6SF2 polymorphism, in end stage hepatic ailment patients with mixed etiology (viral as well as non-viral origin) who received living donor liver transplantation, when compared to normal controls [18].

The reasons for discrepancies observed in the association of PNPLA3 and TM6SF2 variants in the CHC context, including this very study, are not certain but few possibilities can be entertained. Differences in ways to evaluate hepatic fibrosis and cirrhosis i.e. liver biopsy as the gold standard vs use of imaging techniques (such as transient elastography or Fibroscan), and additional variation in elastography thresholds used to define different stages of liver fibrosis and cirrhosis in different clinical settings, may have a part to play. In addition, most studies lack concomitant assessment of hepatosteatosis in CHC settings and functional correlation with lipid profile since these may modulate susceptibility to liver fibrosis and cirrhosis as highlighted in previous studies [10, 11, 17]. Further, study characteristics may display inherent differences especially concerning patient selection (treatment naïve vs those who received prior anti-viral treatment), baseline characteristics (varied prevalence of different HCV genotypes), sample sizes and resultant study powers and data analysis approaches, which may also offer to explain a part of the heterogeneity in these genetic predisposition results. Lastly, population to population dissimilarities in risk allele frequencies for PNPLA3 & TM6SF2 SNPs in general population of Europeans (MAF of 22.6% and 6.8% for PNPLA3 and TM6SF2, respectively) vs Chinese (MAF of 38.3% and 4.4% for PNPLA3 and TM6SF2, respectively) vs Pakistani (MAF of 19.8% and 8.3% for PNPLA3 and TM6SF2, respectively) may also have an effect in this regard.

Data regarding genotype and tissue specific gene expression patterns for PNPLA3 p.I148M and TM6SF2 p.E167K variants and their functional significance are limited [10, 17, 44, 45]. Therefore, we used the modern GTEx database to determine influence of PNPLA3 p.I148M and TM6SF2 p.E167K variants on their respective gene expression, however, no genotype specific modulation of hepatic or visceral adipose tissue gene expression of PNPLA3 and TMS6F2 was evident. This finding is consistent with gene expression studies on NAFLD and CHC patient samples [10, 44], but contrary to a couple of available reports [17, 45]. These data largely emphasizes and support that PNPLA3 and TM6SF2 missense variants may effect function and/or structure of their coded proteins rather than gene expression [6, 23, 27]. This functional mechanistic clarification may be of relevance in designing any therapeutic manipulation of PNPLA3 and TM6SF2 in liver pathologies in future.

This study is not without some limitations. First, absence of metabolic and serum lipid profiles and assessments of steatosis and steatohepatitis data considering lipid metabolism related effects of PNPLA3 and especially TM6SF2 variants analyzed is a limitation, which would have otherwise provided useful insights to the study in this regard. Second, diabetes mellitus status (a known significant risk factor for the development of liver cirrhosis in CHC patients), including any Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) data, was not available and hence, regression models analyzing association of PNPLA3 and TM6SF2 variants were not adjusted for any potential effects of diabetes mellitus status, which adds to the limitations of this study. Third, though we tried to use a sizeable sample set of 502 CHC patients for the present study, the sample sizes in the stratified analyses were rather small and may have rendered association tests for TM6SF2 variant underpowered as suggested by power of study calculations.

In conclusion, PNPLA3 and TM6SF2 genetic polymorphisms do not appear as major determinants of liver scarring in Pakistani patients with CHC and may be of more relevance to CLP with dysregulated hepatic fat such as NAFLD. Further studies with large sample sizes, simultaneous assessment of metabolic and lipid related histological profiles and having functional analyses support in diverse ethnicities may elucidate potential role and clinical utility of PNPLA3 and TM6SF2 genetic testing in CHC mediated liver scarring.

All data generated or analyzed during this study are included in this published article (and its supplementary information files including Additional file 10 for raw sample set data).

Homeostatic model assessment for insulin resistance

Hepatitis C fact sheet [https://www.who.int/news-room/fact-sheets/detail/hepatitis-c].

Mahmud S, Al Kanaani Z, Abu-Raddad LJ. Characterization of the hepatitis C virus epidemic in Pakistan. BMC Infect Dis. 2019;19(1):809.

PubMed  PubMed Central  Article  CAS  Google Scholar 

Eslam M, George J. Genome-wide association studies and hepatitis C: harvesting the benefits of the genomic revolution. Semin Liver Dis. 2015;35(4):402–20.

Cardoso AC, Perez RM, de Figueiredo-Mendes C, Carvalho Leite N, Moraes-Coelho HS, Villela-Nogueira CA. Prevalence and predictive factors of moderate/severe liver steatosis in chronic hepatitis C (CHC) infected patients evaluated with controlled attenuation parameter (CAP). J Viral Hepat. 2018;25(11):1244–50.

CAS  PubMed  Article  Google Scholar 

Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, Boerwinkle E, Cohen JC, Hobbs HH. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40(12):1461–5.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Kozlitina J, Smagris E, Stender S, Nordestgaard BG, Zhou HH, Tybjærg-Hansen A, Vogt TF, Hobbs HH, Cohen JC. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2014;46(4):352–6.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Dong XC. PNPLA3—a potential therapeutic target for personalized treatment of chronic liver disease. Front Med. 2019. https://doi.org/10.3389/fmed.2019.00304 (Lausanne).

Niriella MA, Pathmeswaran A, De Silva ST, Kasturiratna A, Perera R, Subasinghe CE, Kodisinghe K, Piyaratna C, Rishikesawan V, Dassanayaka AS, et al. Incidence and risk factors for non-alcoholic fatty liver disease: A 7-year follow-up study among urban, adult Sri Lankans. Liver Int. 2017;37(11):1715–22.

CAS  PubMed  Article  Google Scholar 

Zhang Y, Guo T, Yang F, Mao Y, Li L, Liu C, Sun Q, Li Y, Huang J. Single-nucleotide rs738409 polymorphisms in the PNPLA3 gene are strongly associated with alcoholic liver disease in Han Chinese males. Hepatol Int. 2018;12(5):429–37.

Petta S, Vanni E, Bugianesi E, Rosso C, Cabibi D, Cammà C, Di Marco V, Eslam M, Grimaudo S, Macaluso FS, et al. PNPLA3 rs738409 I748M is associated with steatohepatitis in 434 non-obese subjects with hepatitis C. Aliment Pharmacol Ther. 2015;41(10):939–48.

CAS  PubMed  Article  Google Scholar 

Huang C-M, Chang K-C, Hung C-H, Chiu K-W, Lu S-N, Wang J-H, Chen C-H, Kee K-M, Kuo Y-H, Tsai M-C, et al. Impact of PNPLA3 and IFNL3 polymorphisms on hepatic steatosis in Asian patients with chronic hepatitis C. PLoS ONE. 2017;12(8):e0182204.

PubMed  PubMed Central  Article  CAS  Google Scholar 

Trépo E, Romeo S, Zucman-Rossi J, Nahon P. PNPLA3 gene in liver diseases. J Hepatol. 2016;65(2):399–412.

PubMed  Article  CAS  Google Scholar 

De Benedittis C, Bellan M, Crevola M, Boin E, Barbaglia MN, Mallela VR, Ravanini P, Ceriani E, Fangazio S, Sainaghi PP, et al. Interplay of PNPLA3 and HSD17B13 variants in modulating the risk of hepatocellular carcinoma among hepatitis C patients. Gastroenterol Res Pract. 2020;2020:4216451.

PubMed  PubMed Central  Article  Google Scholar 

Basyte-Bacevice V, Skieceviciene J, Valantiene I, Sumskiene J, Petrenkiene V, Kondrackiene J, Petrauskas D, Lammert F, Kupcinskas J. TM6SF2 and MBOAT7 gene variants in liver fibrosis and cirrhosis. Int J Mol Sci. 2019;20(6):1277.

CAS  PubMed Central  Article  Google Scholar 

Roh Y-S, Loomba R, Seki E. The TM6SF2 variants, novel genetic predictors for nonalcoholic steatohepatitis. Gastroenterology. 2015;148(1):252–4.

Boyer A, Park SB, de Boer YS, Li Q, Liang TJ. TM6SF2 promotes lipidation and secretion of hepatitis C Virus in infected hepatocytes. Gastroenterology. 2018;155(6):1923-1935.e1928.

CAS  PubMed  Article  Google Scholar 

Eslam M, Mangia A, Berg T, Chan HLY, Irving WL, Dore GJ, Abate ML, Bugianesi E, Adams LA, Najim MAM, et al. Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes. Hepatology. 2016;64(1):34–46.

CAS  PubMed  Article  Google Scholar 

Raja AM, Ciociola E, Ahmad IN, Dar FS, Naqvi SMS, Moaeen-Ud-Din M, Kaukab Raja G, Romeo S, Mancina RM. Genetic susceptibility to chronic liver disease in individuals from Pakistan. Int J Mol Sci. 2020;21(10):3358.

Rauff B, Amar A, Chudhary SA, Mahmood S, Tayyab GUN, Hanif R. Interferon-λ rs12979860 genotype association with liver fibrosis in chronic hepatitis C (CHC) patients in the Pakistani population. Arch Virol. 2021;166(4):1047–56. https://doi.org/10.1007/s00705-020-04901-2.

CAS  Article  PubMed  Google Scholar 

Ziol M, Handra-Luca A, Kettaneh A, Christidis C, Mal F, Kazemi F, Lédinghen VD, Marcellin P, Dhumeaux D, Trinchet J-C, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology. 2005;41(1):48–54.

Hussain A, Gul MA, Khalid MU. Validation of Novel Fibrosis Index (NFI) for assessment of liver fibrosis: comparison with transient elastography (FibroScan). BMJ Open Gastroenterol. 2019;6(1):e000316.

PubMed  PubMed Central  Article  Google Scholar 

Pingitore P, Pirazzi C, Mancina RM, Motta BM, Indiveri C, Pujia A, Montalcini T, Hedfalk K, Romeo S. Recombinant PNPLA3 protein shows triglyceride hydrolase activity and its I148M mutation results in loss of function. Biochim Biophys Acta. 2014;1841(4):574–80.

CAS  PubMed  Article  Google Scholar 

Pirazzi C, Adiels M, Burza MA, Mancina RM, Levin M, Ståhlman M, Taskinen M-R, Orho-Melander M, Perman J, Pujia A, et al. Patatin-like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro. J Hepatol. 2012;57(6):1276–82.

CAS  PubMed  Article  Google Scholar 

Mondul A, Mancina RM, Merlo A, Dongiovanni P, Rametta R, Montalcini T, Valenti L, Albanes D, Romeo S. PNPLA3 I148M variant influences circulating retinol in adults with nonalcoholic fatty liver disease or obesity. J Nutr. 2015;145(8):1687–91.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Bruschi FV, Claudel T, Tardelli M, Caligiuri A, Stulnig TM, Marra F, Trauner M. The PNPLA3 I148M variant modulates the fibrogenic phenotype of human hepatic stellate cells. Hepatology. 2017;65(6):1875–90.

CAS  PubMed  Article  Google Scholar 

Smagris E, Gilyard S, BasuRay S, Cohen JC, Hobbs HH. Inactivation of Tm6sf2, a gene defective in fatty liver disease, impairs lipidation but not secretion of very low density lipoproteins. J Biol Chem. 2016;291(20):10659–76.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Prill S, Caddeo A, Baselli G, Jamialahmadi O, Dongiovanni P, Rametta R, Kanebratt KP, Pujia A, Pingitore P, Mancina RM, et al. The TM6SF2 E167K genetic variant induces lipid biosynthesis and reduces apolipoprotein B secretion in human hepatic 3D spheroids. Sci Rep. 2019;9(1):1–12.

Krawczyk M, Rau M, Schattenberg JM, Bantel H, Pathil A, Demir M, Kluwe J, Boettler T, Lammert F, Geier A, et al. Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study. J Lipid Res. 2017;58(1):247–55.

CAS  PubMed  Article  Google Scholar 

Senkerikova R, Frankova S, Jirsa M, Kreidlova M, Merta D, Neroldova M, Chmelova K, Spicak J, Sperl J. PNPLA3 rs738409 G allele carriers with genotype 1b HCV cirrhosis have lower viral load but develop liver failure at younger age. PLoS ONE. 2019;14(9):e0222609.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Magri MC, Manchiero C, Prata TVG, Nunes AKDS, Oliveira Junior JSD, Dantas BP, Tengan FM. The influence of gene-chronic hepatitis C virus infection on hepatic fibrosis and steatosis. Diagn Microbiol Infect Dis. 2020;97(2):115025.

CAS  PubMed  Article  Google Scholar 

Kupcinskas J, Valantiene I, Varkalaitė G, Steponaitiene R, Skieceviciene J, Sumskiene J, Petrenkiene V, Kondrackiene J, Kiudelis G, Lammert F, et al. PNPLA3 and RNF7 gene variants are associated with the risk of developing liver fibrosis and cirrhosis in an eastern European population. J Gastrointestin Liver Dis. 2017;26(1):37–43.

Chromy D, Mandorfer M, Bucsics T, Schwabl P, Bauer D, Scheiner B, Schmidbauer C, Lang GF, Szekeres T, Ferenci P, et al. Prevalence and predictors of hepatic steatosis in patients with HIV/HCV coinfection and the impact of HCV eradication. AIDS Patient Care STDS. 2019;33(5):197–206.

Liu Z, Que S, Zhou L, Zheng S, Romeo S, Mardinoglu A, Valenti L. The effect of the TM6SF2 E167K variant on liver steatosis and fibrosis in patients with chronic hepatitis C: a meta-analysis. Sci Rep. 2017;7(1):1–11.

Huang Z, Guo X, Zhang G, Liang L, Nong B. Correlation between PNPLA3 rs738409 polymorphism and hepatocellular carcinoma: a meta-analysis of 10,330 subjects. Int J Biol Markers. 2019;34(2):117–22.

CAS  PubMed  Article  Google Scholar 

Raksayot M, Chuaypen N, Khlaiphuengsin A, Pinjaroen N, Treeprasertsuk S, Poovorawan Y, Tanaka Y, Tangkijvanich P. Independent and additive effects of PNPLA3 and TM6SF2 polymorphisms on the development of non-B, non-C hepatocellular carcinoma. J Gastroenterol. 2019;54(5):427–36.

CAS  PubMed  Article  Google Scholar 

Yang J, Trépo E, Nahon P, Cao Q, Moreno C, Letouzé E, Imbeaud S, Gustot T, Deviere J, Debette S, et al. PNPLA3 and TM6SF2 variants as risk factors of hepatocellular carcinoma across various etiologies and severity of underlying liver diseases. Int J Cancer. 2019;144(3):533–44.

CAS  PubMed  Article  Google Scholar 

Miyaaki H, Miuma S, Taura N, Shibata H, Soyama A, Hidaka M, Takatsuki M, Eguchi S, Nakao K. PNPLA3 as a liver steatosis risk factor following living-donor liver transplantation for hepatitis C. Hepatol Res. 2018;48(3):E335–9.

CAS  PubMed  Article  Google Scholar 

Trunečka P, Míková I, Dlouhá D, Hubáček JA, Honsová E, Kolesár L, Lánská V, Fraňková S, Šperl J, Jirsa M, et al. Donor PNPLA3 rs738409 genotype is a risk factor for graft steatosis. A post-transplant biopsy-based study. Dig Liver Dis. 2018;50(5):490–5.

PubMed  Article  CAS  Google Scholar 

Hai H, Tamori A, Thuy LTT, Yoshida K, Hagihara A, Kawamura E, Uchida-Kobayashi S, Morikawa H, Enomoto M, Murakami Y, et al. Polymorphisms in MICA, but not in DEPDC5, HCP5 or PNPLA3, are associated with chronic hepatitis C-related hepatocellular carcinoma. Sci Rep. 2017;7(1):11912.

PubMed  PubMed Central  Article  CAS  Google Scholar 

Yen Y-H, Tsai M-C, Wu C-K, Chang K-C, Hung C-H, Chiu K-W, Lu S-N, Wang J-H, Chen C-H, Kee K-M, et al. Association between PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma in Asian chronic hepatitis C patients: a longitudinal study. J Formos Med Assoc. 2018;117(9):833–40.

CAS  PubMed  Article  Google Scholar 

Degasperi E, Galmozzi E, Facchetti F, D’Ambrosio R, Soffredini R, Borghi M, Perbellini R, Iavarone M, Sangiovanni A, Lampertico P. Clinical but not genetic variables predict the development of hepatocellular carcinoma in hepatitis C cirrhotic patients treated with direct acting antivirals: a 3-year study in 509 patients. Dig Liver Dis. 2019;51:e67.

Urzúa Manchego Á, Mezzano G, Brahm Barril J, Poniachik Teller J, Miranda J, Carreno L, Venegas Santos M. TM6SF2 rs58542926 polymorphism is not associated with risk of steatosis or fibrosis in chilean patients with chronic hepatitis C. Hepat Mon. 2017. https://doi.org/10.5812/hepatmon.44365.

Oliveira AIN, Malta FM, Zitelli PMY, Salles APM, Gomes-Gouvea MS, Nastri ACS, Pinho JRR, Carrilho FJ, Oliveira CP, Mendes-Corrêa MC, et al. The role of PNPLA3 and TM6SF2 polymorphisms on liver fibrosis and metabolic abnormalities in Brazilian patients with chronic hepatitis C. BMC Gastroenterol. 2021;21(1):81.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Valenti L, Al-Serri A, Daly AK, Galmozzi E, Rametta R, Dongiovanni P, Nobili V, Mozzi E, Roviaro G, Vanni E, et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology. 2010;51(4):1209–17.

CAS  PubMed  Article  Google Scholar 

Sookoian S, Castaño GO, Scian R, Mallardi P, Fernández Gianotti T, Burgueño AL, San Martino J, Pirola CJ. Genetic variation in transmembrane 6 superfamily member 2 and the risk of nonalcoholic fatty liver disease and histological disease severity. Hepatology. 2015;61(2):515–25.

CAS  PubMed  Article  Google Scholar 

We acknowledge and thank for all the help provided by Lahore General Hospital, Lahore, Pakistan (especially Prof. Dr. Ghias Un Nabi Tayyab), Westmead Hospital and University of Sydney, NSW, Australia, and University of Health Sciences, Lahore, Pakistan regarding collection, processing and analysis of study samples. We also thank all the patients for their participation in this study.

This work was supported by Higher Education Commission (HEC) Start up Research Grant (SRGP) number –NO: 21-2060/SRGP/R&D/HEC/2018 to BR. The funding body had no role in the design of the study, collection, analysis, and interpretation of data and in writing the manuscript.

Ali Amar and Bisma Rauff are joint senior authors

Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, Sydney, NSW, Australia

Department of Biomedical Engineering, University of Engineering and Technology, Lahore, Narowal Campus, Narowal, Pakistan

Department of Clinical Laboratory Sciences, Jouf University, Sakaka, Kingdom of Saudi Arabia

Institute of Biomedical and Allied Health Sciences, University of Health Sciences, Lahore, Pakistan

Shafiq A. Chudhary & Saqib Mahmood

Department of Medicine, Lahore General Hospital, Lahore, Pakistan

Department of Human Genetics and Molecular Biology, University of Health Sciences, Lahore, Pakistan

Munir Ahmad Bhinder & Ali Amar

Department of Biological Sciences, National University of Medical Sciences, Rawalpindi, Pakistan

You can also search for this author in PubMed  Google Scholar

You can also search for this author in PubMed  Google Scholar

You can also search for this author in PubMed  Google Scholar

You can also search for this author in PubMed  Google Scholar

You can also search for this author in PubMed  Google Scholar

You can also search for this author in PubMed  Google Scholar

You can also search for this author in PubMed  Google Scholar

You can also search for this author in PubMed  Google Scholar

BR conceived and designed the study and received funding. SAC and BN collected samples and performed experiments. BR performed data acquisition and collection. AA did data analysis and interpretations. AA, BR and BA prepared the first draft. AA, BR, BA, SM, MAB and MF critically revised the manuscript. All authors approved the final manuscript.

This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethical Review Committee (ERC) and Advanced Studies and Research Board (ASRB) of University of Health Sciences, Lahore. All patients provided written informed consent for study participations.

The authors declare that they have no competing interests.

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Baseline characteristics according to fibrosis (Metavir) stages.

Distribution of alleles and genotypes for PNPLA3 rs738409 and TM6SF2 rs58542926 polymorphisms and association tests with respect to advanced hepatic fibrosis.

Risk factors for the development of advanced hepatic fibrosis in the present CHC cohort.

Genetic association analyses of PNPLA3 variant (recessive model) with (a) significant hepatic fibrosis (≥ F2), (b) advanced hepatic fibrosis (≥ F3), and (c) hepatic cirrhosis (F4) after stratification of CHC patients into obese and non-obese groups based on BMI status.

Genetic association analyses of TM6SF2 variant (dominant model) with (a) significant hepatic fibrosis (≥ F2), (b) advanced hepatic fibrosis (≥ F3), and (c) hepatic cirrhosis (F4) after stratification of CHC patients into obese and non-obese groups based on BMI status.

eQTL and sQTL analysis for PNPLA3*rs738409 using GTEx database.

eQTL analysis for TM6SF2*rs58542926 using GTEx database.

Multi-tissue eQTL comparison for PNPLA3*rs738409 using GTEx dataset.

Multi-tissue eQTL comparison for TM6SF2*rs58542926 using GTEx dataset.

Raw sample set data for Pakistani CHC patients.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Rauff, B., Alzahrani, B., Chudhary, S.A. et al. PNPLA3 and TM6SF2 genetic variants and hepatic fibrosis and cirrhosis in Pakistani chronic hepatitis C patients: a genetic association study. BMC Gastroenterol 22, 401 (2022). https://doi.org/10.1186/s12876-022-02469-6

DOI: https://doi.org/10.1186/s12876-022-02469-6

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

By using this website, you agree to our Terms and Conditions, California Privacy Statement, Privacy statement and Cookies policy. Manage cookies/Do not sell my data we use in the preference centre.

© 2022 BioMed Central Ltd unless otherwise stated. Part of Springer Nature.